Replies to post #137041 on Biotech Values

[DewDiligence]

The pricing anomalies with respect to Lipitor should be sorted out when the 180-day exclusivity period for Ranbaxy’s and WPI’s generics expire in May 2012. Or possibly sooner. Regards, Dew

[DewDiligence]

Confirming the statement in #msg-72102237 that Lipitor co-payments would sort themselves out when the 180-day Hatch-Waxman period ends this month:

http://online.wsj.com/article/SB10001424052702304543904577394263634380548.html

Independence Blue Cross, in the Philadelphia area, had assigned Lipitor its lowest, $14 co-pay for the first six months after limited generics entered the market. But after that first 180 days, when more generics will be allowed to enter the market, the plan will give that preferred status to a generic starting June 1 and Lipitor's co-pay will rise to about $45.

Regards, Dew